Eravacycline as a last resort for difficult-to-treat resistant <i>Acinetobacter baumannii</i> infections in critically ill patients: three case reports with pharmacokinetic insights
Eravacycline showed promise as a salvage therapy for DTR <i>A. baumannii</i> VAP in critically ill patients. Further studies are needed to confirm its efficacy and optimal dosing in this setting.
Authors
- Léo Mimram (ORCID: https://orcid.org/0009-0002-3101-693X)
- Emilie Rondinaud
- Jean‐François Timsit (ORCID: https://orcid.org/0000-0002-6063-7383)
- Michaël Thy (ORCID: https://orcid.org/0000-0001-9366-505X)
- Minh Lê (ORCID: https://orcid.org/0000-0002-4670-8288)
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- Sorbonne Université (FR)
- Université Sorbonne Paris Nord (FR)
- Sorbonne Paris Cité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Bichat-Claude-Bernard (FR)
Publication Details
- Journal
- JAC-Antimicrobial Resistance
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1093/jacamr/dlaf095
- Citations
- 3
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 1.77